Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00794417 · ClinicalTrials.gov registry record · Phase 1
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00794417 is a Phase 1 study that was terminated before completion, run by Regeneron Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00794417, a Phase 1 study, was terminated before completion, sponsored by Regeneron Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of the study was to determine whether the combination of aflibercept, pemetrexed and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC).
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-11-30 |
| Est. Completion | 2011-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00794417
The ClinicalTrials.gov registry entry for NCT00794417 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00794417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00794417 about?
NCT00794417 is a clinical study titled "A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma". The purpose of the study was to determine whether the combination of aflibercept, pemetrexed and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC).
What is the current status of trial NCT00794417?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2008-11-30. Estimated completion is 2011-06-30.
What interventions are being tested in trial NCT00794417?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), Aflibercept (DRUG).
Who is sponsoring clinical trial NCT00794417?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.